Zeke Capital Advisors, LLC Nektar Therapeutics Transaction History

Zeke Capital Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 17, 2020	SELL	$15.87 - $23.12 $414,778 - $604,264	-26,136 Closed	0 $0
Q3 2019 Oct 18, 2019	BUY	$16.91 - $36.27 $441,959 - $947,952	26,136 New	26,136 $476,000
Q4 2018 Feb 11, 2019	SELL	$30.43 - $56.65 $260,906 - $485,717	-8,574 Closed	0 $0
Q3 2018 Nov 08, 2018	BUY	$46.46 - $68.49 $49,758 - $73,352	1,071 Added 14.27%	8,574 $523,000
Q2 2018 Jul 24, 2018	SELL	$46.25 - $104.45 $133,477 - $301,442	-2,886 Reduced 27.78%	7,503 $366,000

Q1 2018 May 03, 2018	BUY	$57.4 - $108.44 $186,377 - $352,104	3,247 Added 45.46%	10,389 $1.1 Million
Q4 2017 Feb 14, 2018	BUY	$23.02 - $60.5 $164,408 - $432,091	7,142	7,142 $427,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Zeke Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Zeke Capital Advisors, LLC with notifications on news.